Given the documented effectiveness of GLUT-1 inhibitors in various cancer cells (lymphoma, prostate cancer, gastric cancer) [24] we examined the effect of our GLUT-1 inhibitors on mesothelioma cells. Here, SLC2A1 is linked to gastric cancer.